Pharmaceuticals.jpg

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

104746-04-5

Eslicarbazepine

104746-04-5
56839-43-1

Eperisone HCl

56839-43-1
53-42-9

Etiocholanolone

53-42-9
177834-92-3

Eletriptan hydrobromide

177834-92-3
915087-33-1

Enzalutamide

915087-33-1
143491-57-0

Emtricitabine

143491-57-0
566-76-7

16alpha-hydroxy Estrone

566-76-7
94105-90-5

Equol

94105-90-5
183319-69-9

Erlotinib HCl

183319-69-9
76095-16-4

Enalapril Maleate USP

76095-16-4
217087-09-7

Esomeprazole Magnesium USP

217087-09-7
40158-95-0

Erucifoline

40158-95-0
NA

Etoposide Resolution Mixture USP

NA
76-58-4

Ethylmorphine

76-58-4
27521-34-2

6alpha-Hydroxy Ethynyl Estradiol

27521-34-2
56324-28-8

6beta-Hydroxy Ethynyl estradiol

56324-28-8
38002-18-5

6-Keto Ethynyl Estradiol

38002-18-5
67703-68-8

6,7-Dehydro Ethynyl Estradiol

67703-68-8
217087-09-7

Esomeprazole Magnesium

217087-09-7
202409-33-4

Etoricoxib

202409-33-4